Mechanistically, HSPD1 has been demonstrated to promote EMT and osteosarcoma progression by inhibiting ATP5A1 ubiquitination-dependent degradation and activating downstream AKT/mTOR signaling. Here, ATP5F1A is linked to osteosarcoma.